Off-label / FDA Approved (Spravato)
Mixed Insurance Coverage
Ketamine Therapy
Ketamine is an NMDA receptor antagonist that demonstrates rapid-acting antidepressant and anti-suicidal effects, often providing relief within hours rather than weeks.
How it Works
Unlike traditional SSRIs that target serotonin, Ketamine targets the glutamate system in the brain, promoting synaptogenesis (the growth of new neural connections) in areas damaged by chronic stress and depression.
The primary modalities are Intravenous (IV) infusions, Intramuscular (IM) injections, oral lozenges/troches, and the FDA-approved Esketamine nasal spray (Spravato).
Clinical Efficacy
The Data: Real-World Outcomes
- Response Rate: ~50-70% of TRD patients show a rapid, clinically significant response (≥50% reduction in symptoms).
- Durability: Acute response is rapid but transient. Most patients require an initial series of 6 infusions over 2-3 weeks, followed by maintenance "booster" infusions every 3-8 weeks to sustain remission.
- Anti-Suicidal Effect: Demonstrates a unique, rapid reduction in suicidal ideation compared to any other psychiatric intervention.
Cost Breakdown
| Modality | Cost per Session | Insurance Coverage |
|---|---|---|
| IV Infusion | $400 - $800 | Rarely covered. Superbills may reimburse the medical evaluation portion. |
| Spravato (Nasal) | $20 - $100 (Copay) | Widely covered for TRD with prior authorization. |
| Oral Lozenges | $100 - $250 (Monthly) | Not covered (Compounded medication). |
Side Effects & Risks
During the treatment (acute effects lasting 1-2 hours):
- Dissociation or feeling "out of body"
- Nausea and dizziness
- Elevated blood pressure and heart rate (requiring clinical monitoring)